Summary
Novavax continues to make progress with multiple vaccine programs.
Running multiple trials have caused massive shareholder dilution in the last couple of years with the share count soaring to 376 million.
The small biotech needs a partner to fund one of the vaccine programs before investing makes sense.
As Novavax (NVAX) continues to make progress towards multiple vaccine approvals in the next couple of years, the stock isn't gaining any traction. The company finally mentioned finding a potential partner as the cash burn remains relentless. The biotech stock only gets interesting under this scenario.

Image Source: Novavax website
Program Updates
Anybody following my previous research knows that my biggest complaint about Novavax is that the company has historically shifted both drug priorities and deadlines. The end result is a lot of promise and no actual results.
The small biotech continues to see promising trial data from both the ResVax and NanoFlu programs. During last quarter, the Prepare trial reached the enrollment goals and now all the involved babies have been born starting the clock on the 180 days needed to observe the trial's results. As well, NanoFlu is moving forward towards Phase 2 trials. A couple of promising vaccines for a stock with a market value only around $500 million.

